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INTRODUCTION
Intrathecal anesthesia is an easy and preferable 
technique for transurethral endoscopic surgery, 
as it provides effective sensory and motor block 
with rapid onset, reduces hospital length of stay, 
and postoperative pain.1,2 Hyperbaric bupivacaine 
is a commonly used local anesthetic solution for 
intrathecal anesthesia. The hyperbaric solution is 
expected to provide more predictable block because 
it tends to spread according to gravity. Bupivacaine is 
a racemic mixture of S (-) and R (+) enantiomers.1,3 
The two enantiomers have exactly similar in physi-
cochemical properties but can have different affinity 
for the side of action or the side effects. The differ-
ential affinity of each enantiomer for sodium, potas-
sium, and calcium channels results in a significant 
reduction of neurological dan cardiac toxicity of the 
S-enantiomer in comparison to the R-enantiomer.4 
Levobupivacaine is the S (-) or Levo enan-
tiomers of bupivacaine.1,3,4 In many countries, 
levobupivacaine is only available in isobaric solu-
tion. Isobaric solution for intrathecal anesthesia 
is less popular because of the fear that the block 
spreading is unpredictable. Therefore, we report 
this case series to prove that isobaric levobupiva-
caine is effective clinically (it can become a better 
alternative to hyperbaric bupivacaine in intrathecal 
anesthesia) with better safety profile because it has 
lower toxic effects on the central nervous system 
and cardiovascular. 
CASE SERIES
Six patients with the aged ranged from 40 to 78 years 
old with American Society of Anesthesiology 
(ASA) physical status II-III, were scheduled for 
elective transurethral endoscopic surgery under 
intrathecal anesthesia. From their physical exam-
ination revealed no vertebra anomaly. Laboratory 
and radiology examination finding no coagulopa-
thy nor spinal metastases. 
Peripheral IV lines (18G) were secured. All of 
the patients received premedication with 1 mg of 
intravenous midazolam, 10 mg dexamethasone, 
and 10 mg diphenhydramine. 5 ml/kg of ringer 
lactate was commenced to preload the patient 
before intrathecal anesthesia. In the operating 
theatre, standard monitoring was applied to the 
patient. Baseline vitals were recorded. Oxygen 
2  L/min was administered via nasal cannula. The 
patient was placed in a left lateral position and then 
took all aseptic precautions, a 27 G Quincke’s spinal 
needle was introduced via a midline approach 
in L2-L3 interspace. Correct needle placement 
was identified by free-flowing cerebrospinal fluid 
(CSF), and 12.5 mg isobaric levobupivacaine was 
injected in subarachnoid space. After the injection, 
the patient was placed into a supine position with 
a small pillow under the head. Sensory and motor 
block characteristics can be seen in table 1. After 
achieving complete sensory (as high as minimal 
thoracic 10) and motor block (Bromage score of 3), 
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Abstract
The search for safer anesthetic solutions has always been one of the 
primary needs in anesthesiology practice. Levobupivacaine, the 
pure S (-) enantiomer of bupivacaine, emerged as a safer alternative 
for intrathecal anesthesia than its racemic parent (bupivacaine). 
Levobupivacaine shows a lower risk of the central nervous system and 
cardiovascular toxicity. However, in many countries, levobupivacaine 
is only available in isobaric solution, where the isobaric solution for 
intrathecal anesthesia is still often be questioned its effectiveness 
because of the fear that the block spreading is unpredictable. In this 
case series, we describe sensory and motor block characteristics, 
hemodynamics profile and adverse effects of isobaric levobupivacaine 
in intrathecal anesthesia for six patients with American Society of 
Anesthesiology physical status II-III whose undergo transurethral 
endoscopic surgery.
Keywords: levobupivacaine, isobaric, intrathecal anesthesia
Cite This Article: Senapathi, T.G.A., Widnyana, I.M.G., Nada, I.K.W., Astuti, M.K. 2019. Isobaric levobupivacaine for intrathecal anesthesia 
as an effective and safe option in transurethral resection of the prostate surgery. Bali Journal of Anesthesiology 3(2): 146-149. DOI:10.15562/
bjoa v3i2.187
Isobaric levobupivacaine for intrathecal anesthesia 
as an effective and safe option in transurethral 
resection of the prostate surgery
Tjokorda Gde Agung Senapathi,* I Made Gede Widnyana, I Ketut Wibawa Nada,  
Mira Kusuma Astuti
147Published by DiscoverSys | Bali Journal of Anesthesiology 2019; 3(2): 146-149 | doi: 10.15562/bjoa.v3i2.187
ORIGINAL ARTICLE
the patient is positioned into a lithotomy position. 
During surgery, the patient remained hemodynam-
ically stable (table 2). No additional vasopressor 
was given. Side effects such as nausea, vomiting, 
bradycardia (heart rate less than 50x/min), hypo-
tension (fall in basal blood pressure more than 
25%), or shivering were recorded during surgery. 
The surgery lasted for 40-70 minutes. Postoperative 
analgesia was maintained with paracetamol tablet 
500 mg every 6 hours and tramadol 50 mg for addi-
tional systemic analgesia if needed.
DISCUSSION
Levobupivacaine was developed following concerns 
of the serious central nervous system (CNS) and 
cardiovascular adverse reactions after inadvertent 
systemic spreading of bupivacaine.1,4,5 The uptake 
of bupivacaine by the central nervous cells is 
enantio-selective. Thus both levobupivacaine and 
ropivacaine are much safer compared to bupiva-
caine. Their convulsive threshold is found to be 
higher in various animal models, leading to fewer 
CNS symptoms after intravenous administration 
in human volunteers and fewer excitatory changes 
in the electroencephalogram than bupivacaine.6 
In human studies, the mean dose of intravenous 
levobupivacaine and bupivacaine associated 
with CNS symptoms was similar, 56-68 mg and 
48-65 mg, respectively. At this similar dose, levobu-
pivacaine shows less myocardial contractility and 
atrioventricular conduction depressant effect than 
bupivacaine significantly.7,8
The cardiotoxic effects of local anesthetics follow 
a two-stage pathway: an initial activation of the 
sympathetic nervous system during the CNS excit-
atory phase leads to tachycardia and hypertension 
that can mask direct myocardial depression followed 
by arrhythmias and profound contractile dysfunc-
tion.9 There seems a dose-dependent prolongation 
of cardiac conduction with the use of local anes-
thetics leading to an increase in the PR interval and 
QRS duration on the electrocardiogram. This is due 
to the persistent blockade of sodium channels into 
diastole, predisposing to re-entrant arrhythmias 
depending on the drugs dissociation. As bupiva-
caine takes ten times more time to dissociate than 
that of lidocaine, its blockade can accumulate, 
resulting in a more marked cardiac depression.4 
The pure enantiomers (ropivacaine and levobupi-
vacaine) have less myocardial depressant profile 
than racemic bupivacaine. The levorotatory isomer 
Table 1  Profile of sensory and motoric block for each patient in this study
During Surgery Patient I Patient II Patient III Patient IV Patient V Patient VI
Time to onset of sensory block (T10) (min) 8 4 4 5 5 4
Time to onset of motor block (Bromage>0) (min) 4 5 2 4 3 3
Time to onset of complete motor block (Bromage=3) (min) 7 7 6 9 8 6
Highest level of sensory block T8 T6 T6 T6 T6 T6
Time to T12 regression of sensory block (min) 130 120 132 150 158 159
Time to recovery of motor block (Bromage=0) (min) 210 220 212 194 218 199
Table 2  Intraoperative hemodynamics for each subject
Hemodynamics during surgery Patient I Patient II Patient III Patient IV Patient V Patient VI
Sistole (mmHg) 135-150 105-115 95-107 108-138 95-114 126-165
Diastole (mmHg) 75-89 69-75 56-63 67-91 53-65 72-81
Heart rate (beats/min) 68-81 55-78 52-71 79-105 54-68 56-72
Respiratory rate (breaths/min) 12-15 12-14 12-15 14-16 12-15 12-14
SpO2 (%) 98-99 98-100 98-100 97-99 97-99 97-99
Table 3  Intraoperative adverse events for each subject
Intraoperative adverse events Patient I Patient II Patient III Patient IV Patient V Patient VI
Nausea no no no no no no
Vomiting no no no no no no
Bradycardia no no no no no no
Hypotension no no no no no no
Shivering no yes no yes yes no
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is sevenfold less potent in blocking the potassium 
channel and hence, decreases the propensity to 
prolong OTc interval.4 
Levobupivacaine (like other local anesthetic 
agents) exerts its effects on neuronal membranes 
by binding sodium ion channels reversibly at the 
nodes of Ranvier in myelinated nerves, leading to 
faster onset as compared to unmyelinated nerves, 
therefore preventing voltage-dependent increases 
in sodium-ion conductance, ultimately inhibiting 
the initiation and propagation of action potentials in 
neuronal cells. Levobupivacaine blocks small diam-
eter neuronal fibers more readily than large fibers, 
explaining the blocking of nociception before other 
sensory modalities.3,4 It is > 97% plasma protein-
bound (mainly to α1-acid glycoprotein), compares 
to 95% racemic bupivacaine. Less than 3% of the 
drug circulates free in plasma so that it can cause an 
action on the other tissues causing unexpected side 
effects and toxic manifestations.1 Its high plasma 
protein binding and high lipid solubility seem to 
explain its prolonged duration of action, while its 
pKa (higher than that of lignocaine) explains its 
slower onset of action, as less of the drug will be 
unionised at physiological pH.3
Levobupivacaine is extensively metabolized in 
the liver by hepatic cytochrome (CYP) CYP3A4 
isoform and CYPP1A2 isoform to inactive metab-
olites, desbutyl levobupivacaine and 3-hydroxy 
levobupivacaine. 3-hydroxy levobupivacaine will 
undergo further transformation to glucuronide 
acid and sulfate ester conjugates, which excreted in 
urine (about 71% within 48 hours), while 24% was 
in feces.1,4
Levobupivacaine produces an intrathecal block 
with similar characteristics of sensory and motor 
block, and also recovery like bupivacaine.1 The 
onset of sensory and motor block is hastened with 
the use of hyperbaric levobupivacaine as compared 
with isobaric levobupivacaine.10 The regression 
of motor block occurs earlier with levobupiva-
caine as compared to bupivacaine.11,12 Intrathecal 
administration of levobupivacaine with a dosage 
of 15 mg provides an adequate sensory and motor 
block lasting for approximately 6.5 hours. Dosage 
of 5-10 mg is used in daily case surgeries. At low 
concentration, levobupivacaine will produce a 
differential block with preservation of motor 
function, which provides benefits for ambulatory 
surgery. Minimum effective local anesthetic dose 
(MLAD) of levobupivacaine as recommend by an 
up and down sequential design study is 11.7 mg.1,5
Baricity is a measure of the relative density of 
local anesthetic solution when compared with 
cerebrospinal fluid (CSF). Local anesthetics have 
baricity which ranges from 0.9990 to 1.0010 are 
isobaric.13 Local anesthetics are made hyperbaric 
by adding glucose, which increases its mass density. 
Hyperbaric solutions are generally preferred in 
intrathecal anesthesia, because they tend to spread 
according to gravity, and can achieve higher peak 
sensory level with faster onset.14 Several reports 
have shown that isobaric bupivacaine spreads unex-
pectedly cephalad, even after a reasonable time is 
allowed for fixation, thus causes late complication 
such as hypotension and bradycardia due to high 
block.15,16 It was explained that all plain anesthetic 
solutions are actually hypobaric in CSF, resulting in 
an excessively high spread.17 In contrast, isobaric 
levobupivacaine is different in this aspect. Its 
block levels are distributed to a narrow range and 
do not spread to higher levels as observed in the 
various study.18,19 Gori et al. described that specific 
gravity of isobaric levobupivacaine is very close 
to CSF, it acts indifferently to gravitational forces, 
both immediately after the injection and later on.19 
Therefore intrathecal isobaric levobupivacaine does 
not spread unexpectedly high, and levels of sensory 
block after spinal isobaric levobupivacaine are 
unaffected by the change in patient position follow-
ing the injection. This might be the advantage over 
plain bupivacaine which tends to spread unexpect-
edly high.14
Transurethral endoscopic surgery requires a 
sensory block of at least thoracic 10 (T10).18 In our 
case series, the highest level of sensory block ranged 
from thoracic 6 (T6) to thoracic 8 (T8). This is by 
the reports from Glaser et al.20, Fattorini et al.21, and 
Vellosillo et al.,22 which said that peak sensory level 
achieved with isobaric levobupivacaine was around 
T8. 
Sen et al.23 performed a study on patients who 
received either 13.5 mg hyperbaric bupivacaine or 
13.5 mg isobaric levobupivacaine for transurethral 
endoscopic surgery, found that the speed of onset 
and offset of motor and sensory blockade were 
significantly quicker with hyperbaric bupivacaine, 
while the extent of maximal block and occurrence 
side effects were similar between the groups. In 
our case series, 3 of 6 patients experienced shiv-
ering during the surgery, but no other side effects 
(nausea, vomiting, bradycardia, hypotension, or 
pruritus) were encountered during surgery.
Isobaric levobupivacaine was found effective 
for surgeries requiring a level of T10 or below like 
TURP,24 lower limb orthopedic surgeries,14 lower 
abdominal surgeries.25,26 For cesarean section, 
isobaric levobupivacaine also proved effective as the 
spreading of spinal anesthetic was found to be more 
cephalic due to gravid uterus achieving desired 
T4/T6 level.12,27 A study by Lee et  al.28, demon-
strated 2.6 ml of 0.5% isobaric levobupivacaine or 
0.5% racemic bupivacaine in urological surgery 
under spinal anesthesia and found that there were 
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no significant differences in the quality of sensory 
and motor block or in hemodynamic change. 
Our case series shows that isobaric levobupiva-
caine is effective in intrathecal anesthesia for trans-
urethral endoscopic surgery as it offers effective 
sensory-motor blockade and stable hemodynamics 
profile. 
CONCLUSION
Levobupivacaine should be considered as an alter-
native to its racemic patent, bupivacaine due to 
better safety profile.
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